Aytu BioPharma (AYTU) Stock Price, News & Analysis

Company Overview

Aytu BioPharma, Inc. is a specialty pharmaceutical company focused on commercializing prescription medicines, primarily for pediatric and primary-care markets. The company’s activities include acquiring, developing and commercializing products intended to address unmet needs in areas such as attention deficit hyperactivity disorder (ADHD), allergies and other common medical conditions.

Aytu’s ADHD portfolio has included Adzenys XR-ODT, an orally disintegrating extended-release amphetamine tablet; Cotempla XR-ODT, an orally disintegrating extended-release methylphenidate tablet; and Dyanavel XR, an extended-release liquid amphetamine formulation. The company has also marketed other prescription and consumer health products over time, with its portfolio subject to change through acquisitions, licensing arrangements and product divestitures.

The company was formed in 2015 through the merger of Aytu BioScience and Nivalis Therapeutics and is headquartered in the United States. Aytu primarily serves the U.S. healthcare market through commercial, distribution and specialty-pharmacy channels. Josh Disbrow has served as the company’s chief executive officer since its formation.

Key Stats

• Today's Range: $2.17 to $2.24
• 50-Day Range: $1.97 to $2.40
• 52-Week Range: $1.65 to $3.07
• Volume: 16,441 shs
• Average Volume: 50,128 shs
• Market Capitalization: $23.59 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $14.50
• Consensus Rating: Hold

Aytu BioPharma Stock Analysis - MarketRank™

Aytu BioPharma scored higher than 60% of companies evaluated by MarketBeat, and ranked 367th out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Hold

Consensus Rating

Aytu BioPharma has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Aytu BioPharma has a consensus price target of $14.50, representing about 568.2% upside from its current price of $2.17.

Amount of Analyst Coverage

Aytu BioPharma has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Aytu BioPharma is -1.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Aytu BioPharma is -1.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Aytu BioPharma has a P/B Ratio of 0.66. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.05% of the float of Aytu BioPharma has been sold short.

Short Interest Ratio / Days to Cover

Aytu BioPharma has a short interest ratio ("days to cover") of 12.88, which indicates bearish sentiment.

Change versus previous month

Short interest in Aytu BioPharma has recently decreased by 6.82%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Aytu BioPharma does not currently pay a dividend.

Dividend Growth

Aytu BioPharma does not have a long track record of dividend growth.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 0.33

News Sentiment

Aytu BioPharma has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 12 news articles for Aytu BioPharma this week, compared to 2 articles on an average week.

Search Interest

1 people have searched for AYTU on MarketBeat in the last 30 days.

MarketBeat Follows

2 people have added Aytu BioPharma to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.6 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Aytu BioPharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

4.90% of the stock of Aytu BioPharma is held by insiders.

Percentage Held by Institutions

33.49% of the stock of Aytu BioPharma is held by institutions.

Company Calendar

• Last Earnings: 5/13/2026
• Today: 9/28/2026
• Lytham Partners Fall 2026 Investor Conference: 9/29/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 6/30/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:AYTU
• CIK: 1385818
• Web: aytubio.com
• Phone: (720) 437-6580
• Fax: N/A
• Employees: 83
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Aytu BioPharma: $14.50
• High Price Target: $14.50
• Low Price Target: $14.50
• Potential Upside/Downside: +568.2%
• Consensus Rating: Hold
• Rating Score (0-4): 2.25
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.66)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 8.68
• P/E Growth: N/A
• Net Income: -$14.25 million
• Net Margins: -24.76%
• Pretax Margin: -24.72%
• Return on Equity: -56.54%
• Return on Assets: -13.14%

Debt

• Debt-to-Equity Ratio: 0.26
• Current Ratio: 1.13
• Quick Ratio: 1.00

Sales & Book Value

• Annual Sales: $57.57 million
• Price / Sales: 0.41
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.29 per share
• Price / Book: 0.66

Miscellaneous

• Outstanding Shares: 10,870,000
• Free Float: 10,335,000
• Market Cap: $23.59 million
• Optionable: Not Optionable
• Beta: 0.26